jag009
★★★

NJ,
2018-09-07 20:31
(1231 d 22:11 ago)

Posting: # 19251
Views: 1,732
 

 FDA Supac guidance for ER [Regulatives / Guidelines]

Hi,

Question. To support SUPAC (post approval manufacturing site change) filing for ER products, do we need to perform multimedia dissolution testings?

Thanks
John
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2018-09-09 14:04
(1230 d 04:39 ago)

@ jag009
Posting: # 19253
Views: 1,438
 

 FDA Supac guidance for ER

Hi John,

» To support SUPAC (post approval manufacturing site change) filing for ER products, do we need to perform multimedia dissolution testings?

Generally not. That’s a Level 3 Change.
See the guidance V. C. 2. b. Dissolution documentation:

In addition to application/compendial release requirements, a multipoint dissolution profile should be obtained using application/compendial test conditions for the changed drug product and the biobatch or marketed batch (unchanged drug product). Adequate sampling should be performed, for example at 1, 2, and 4 hours and every two hours thereafter until either 80% of the drug from the drug product is released or an asymptote is reached.

But don’t forget V. C. 2. c. Bioequivalence documentation:

A single-dose bioequivalence study. The bioequivalence study may be waived in the presence of an established in vitro/in vivo correlation.


Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
jag009
★★★

NJ,
2018-09-10 18:38
(1229 d 00:05 ago)

@ Helmut
Posting: # 19256
Views: 1,393
 

 FDA Supac guidance for ER

Thank Helmut!
Activity
 Admin contact
21,833 posts in 4,568 threads, 1,554 registered users;
online 9 (0 registered, 9 guests [including 8 identified bots]).
Forum time: Friday 17:43 CET (Europe/Vienna)

No problem can stand the assault of sustained thinking.    Voltaire

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5